



Platelet-Rich Plasma (PRP) Injections

Last Revision/Review Date: May 20, 2020

P&P # C.13.01

Policy

This Medical Policy does not constitute medical advice. When deciding coverage, the enrollee’s specific plan document must be referenced. The terms of an enrollee’s plan document (Certificate of Coverage (COC) or Summary Plan Description (SPD)) may differ from this Medical Policy. In the event of a conflict, the enrollee’s specific benefit plan document supersedes this Medical Policy. All reviewers must first identify enrollee eligibility, any federal or state regulatory requirements, and the plan benefit coverage prior to use of this Medical Policy. Other Policies and Coverage Determination Guidelines may apply. Quartz reserves the right, in its sole discretion, to modify its Policies and Guidelines as necessary.

Procedure

Based on the evaluation of medical literature, the safety, efficacy and long-term outcomes; Platelet-Rich Plasma Injections are considered experimental or investigational for all conditions including the following: (*not all-inclusive*)

1. **Musculoskeletal soft tissue injuries:**
 - a. Ligament, muscle or tendon tears;
 - b. Tendinopathies;
 - c. Epicondylitis;
 - d. Plantar fasciitis

2. **Augmentation after surgical repair or reconstruction:**
 - a. Shoulder impingement surgery;
 - b. Rotator cuff tear repair or acromioplasty;
 - c. Anterior cruciate ligament reconstruction (augmentation procedure);
 - d. Acute Achilles tendon rupture surgery;
 - e. ACL donor site.

3. **Wound or Ulcer Healing**

4. **Osteoarthritis of the knee and hip**

CPT CODE NOT COVERED:

0232T	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.
-------	--

REFERENCES:

American Association of Hip and Knee Surgeons. Position Statement on Biologics for advanced hip and knee arthritis. Published Jan 15, 2019. Available at: <http://www.aahks.org/wp-content/uploads/2019/01/AAHKS-Position-Statement-on-Biologics-1.19-1.pdf> Accessed March 27, 2020.

CMS Pub. 100-3 Medicare National Coverage Determinations Manual; Section 270.3 Blood Derived Products for Chronic Non-Healing Wounds. Accessed March 27, 2020.

Hayes, Inc. Comparative Effectiveness Review.

- Comparative effectiveness review of platelet-rich plasma for knee osteoarthritis. A review of reviews. Published November 9, 2017. Annual Review Dec 18, 2019. Accessed March 27, 2020.
- Comparative effectiveness review of platelet-rich plasma for rotator cuff repairs, tendinopathies and related conditions: A review of reviews. Published May 31, 2018. Annual Review Jun 26, 2019. Accessed March 20, 2019.
- Comparative effectiveness review of platelet-rich plasma for tendinopathies or ligament injuries of the knee. Published Dec 27, 2017. Annual Review Mar 14, 2019. Accessed March 27, 2020.
- Comparative effectiveness review of platelet-rich plasma for treatment of conditions of the Achilles Tendon and Plantar Fascia. Published March 14, 2019. Accessed March 27, 2020.
- Comparative effectiveness review of platelet-rich plasma for treatment of lateral epicondylitis: A review of reviews. Published Dec 8, 2017. Annual Review Dec 29, 2019. Accessed March 27, 2020.

Hayes, Inc. Health Technology Assessment.

- Platelet-rich plasma for hip osteoarthritis. Published Jun 14, 2019. Accessed March 27, 2020.

Kolanski SL, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. *Arthritis Care & Research*. 2020;72(2):149-162.

Martinez-Zapata MJ, et.al. Autologous Platelet Rich Plasma for chronic wounds, *Cochrane Database of Systematic Reviews*. 2016, Issue 5. Art. No.: CD006899. DOI: 10.1002/14651858.CD006899.pub3.

Moraes VY, Lenza M, et.al. Platelet-rich therapies for musculoskeletal soft tissue injuries. *Cochrane Database of Systematic Reviews*. 2014, Issue 4. Art. No.: CD010071. DOI: 10.1002/14651858.CD010071.pub3.